Chlamydial antibodies and risk of prostate cancer

被引：27

作者：

Anttila, T

Tenkanen, L

Lumme, S

Leinonen, M

Gislefoss, RE

Hallmans, G

Thoresen, S

Hakulinen, T

Luostarinen, T

Stattin, P

Saikku, P

Dillner, J

Lehtinen, M

Anttila, T

Tenkanen, L

Lumme, S

Leinonen, M

Gislefoss, RE

Hallmans, G

Thoresen, S

Hakulinen, T

Luostarinen, T

Stattin, P

Saikku, P

Dillner, J

Lehtinen, M

Hakama, M ^{[1
]}

机构：

[1] Univ Tampere, Sch Publ Hlth, FIN-33014 Tampere, Finland

[2] Natl Publ Hlth Inst, Oulu, Finland

[3] Helsinki Heart Study, Helsinki, Finland

[4] Janus Serum Bank, Oslo, Norway

[5] Umea Univ Hosp, Dept Publ Hlth & Clin Med Nutr Res, S-90185 Umea, Sweden

[6] Canc Registry Norway, Oslo, Norway

[7] Finnish Canc Registry, FIN-00170 Helsinki, Finland

[8] Umea Univ Hosp, Dept Urol, S-90185 Umea, Sweden

[9] Univ Oulu, Dept Med Microbiol, Oulu, Finland

[10] Malmo Univ Hosp, Dept Microbiol, Malmo, Sweden

来源：

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2005年 / 14卷 / 02期

关键词：

D O I：

10.1158/1055-9965.EPI-03-0325

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: We assessed the risk of prostate cancer by exposure to Chlamydia trachomatis. Method: Seven hundred thirty eight cases of prostate cancer and 2,271 matched controls were identified from three serum sample banks in Finland, Norway, and Sweden by linkage to the population based cancer registries. Results: A statistically significant inverse association (odds ratio, 0.69; 95% confidence interval, 0.51-0.94) was found. It was consistent by different serotypes and there was a consistent dose-response relationship. Conclusion: C. trachomatis infection is not likely to increase the risk of prostate cancer. Whether the inverse relationship is true or due to difficulties in measuring the true exposure in prostatic tissue by serology, confounders or other sources of error remain open.

引用

页码：385 / 389

页数：5

共 61 条

[41]

Ludwig M, 1996, ANN UROL, V30, P139

[42] CHLAMYDIA IN CHRONIC PROSTATITIS [J].